Kite Becomes News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share: -- 93 Percent of Patients in ZUMA-2 Pivotal Trial Responded to Single Infusion of Tecartus -- -- Tecartus is First CAR T Therapy in Relapsed or Refractory MCL and Kite Becomes the First Company with Multiple Approved Cell Therapies in Europe -- Kite, a Gilead Company (NASDAQ:GILD), today announced that the European Commission has granted conditional marketing authorization for Tecartus™ (autologous, anti-CD19-transduced CD3+ cells; formerly KTE-X19). Tecartus is a chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory mantle cell lymphoma after ...

(2) -- 93 Percent of Patients in ZUMA-2 Pivotal Trial Responded to Single Infusion of Tecartus -- -- Tecartus is First CAR T Therapy in Relapsed or Refractory MCL and Kite Becomes the First Company with Multiple Approved Cell Therapies in Europe -- Kite, a Gilead Company (Nasdaq: GILD), today announced that the European Commission has granted conditional marketing authorization for Tecartus (autologous, anti-CD19-transduced CD3+ cells; formerly KTE-X19). Tecartus is a chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory mantle cell lymphoma after two o...

93 Percent of Patients in ZUMA-2 Pivotal Trial Responded to Single Infusion of Tecartus — — Tecartus is First CAR T Therapy in Relapsed or Refractory MCL and Kite Becomes the First Company with Multiple Approved Cell Therapies in Europe — Kite, a Gilead Company today announced that the European Commission has granted conditional marketing authorization for Tecartus™ . Tecartus is a chimeric antigen receptor T … — 93 Percent of Patients in ZUMA-2 Pivotal Trial Responded to Single Infusion of Tecartus — — Tecartus is First CAR T Therapy in Relapsed or Refractory MCL and Kite ...

utologous anti CD19 transduced CD3+ cells Granted Conditional European Marketing Authorisation for Relapsed and Refractory Mantle Cell Lymphoma --   London, UK – 16 December 2020 – Kite, a Gilead Company, today announced that the European Commission has granted conditional marketing authorisation for its autologous anti CD19 transduced CD3+ cells, a chimeric antigen receptor (CAR) T cell therapy, as a treatment for adult patients with relapsed or refractory mantle cell lymphoma after two or more lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor.   The con...